- Home
- DRTS vs MOLN Comparison
DRTS vs MOLN Comparison
Compare DRTS & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRTS
- MOLN
- Stock Information
- Founded
- DRTS 2015
- MOLN 2004
- Country
- DRTS Israel
- MOLN Switzerland
- Employees
- DRTS N/A
- MOLN N/A
- Industry
- DRTS Medical/Dental Instruments
- MOLN
- Sector
- DRTS Health Care
- MOLN
- Exchange
- DRTS Nasdaq
- MOLN Nasdaq
- Market Cap
- DRTS 211.7M
- MOLN 183.2M
- IPO Year
- DRTS N/A
- MOLN 2021
- Fundamental
- Price
- DRTS $2.55
- MOLN $3.81
- Analyst Decision
- DRTS Strong Buy
- MOLN
- Analyst Count
- DRTS 2
- MOLN 0
- Target Price
- DRTS $8.00
- MOLN N/A
- AVG Volume (30 Days)
- DRTS 32.4K
- MOLN 5.0K
- Earning Date
- DRTS 03-12-2025
- MOLN 03-06-2025
- Dividend Yield
- DRTS N/A
- MOLN N/A
- EPS Growth
- DRTS N/A
- MOLN N/A
- EPS
- DRTS N/A
- MOLN N/A
- Revenue
- DRTS N/A
- MOLN $5,484,562.00
- Revenue This Year
- DRTS N/A
- MOLN N/A
- Revenue Next Year
- DRTS N/A
- MOLN $528.57
- P/E Ratio
- DRTS N/A
- MOLN N/A
- Revenue Growth
- DRTS N/A
- MOLN N/A
- 52 Week Low
- DRTS $1.75
- MOLN $3.32
- 52 Week High
- DRTS $4.39
- MOLN $12.70
- Technical
- Relative Strength Index (RSI)
- DRTS 39.29
- MOLN 38.23
- Support Level
- DRTS $2.60
- MOLN $3.76
- Resistance Level
- DRTS $2.68
- MOLN $4.56
- Average True Range (ATR)
- DRTS 0.14
- MOLN 0.31
- MACD
- DRTS 0.01
- MOLN -0.01
- Stochastic Oscillator
- DRTS 28.26
- MOLN 5.78
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. The Alpha CaRT technology of the company utilizes the therapeutic properties of alpha particles aiming to overcome, and harness for benefit for alpha radiation's range. The company derives maximum revenue from Israel.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.